Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for IceCure Medical (ICCM) over the last 6 years, with Q3 2025 value amounting to $7.5 million.

  • IceCure Medical's Cash from Financing Activities rose 12229.83% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year increase of 6206.77%. This contributed to the annual value of $9.2 million for FY2024, which is 1096867.47% up from last year.
  • IceCure Medical's Cash from Financing Activities amounted to $7.5 million in Q3 2025, which was up 12229.83% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, IceCure Medical's Cash from Financing Activities ranged from a high of $16.2 million in Q4 2021 and a low of $7000.0 during Q3 2021
  • For the 5-year period, IceCure Medical's Cash from Financing Activities averaged around $5.1 million, with its median value being $2.8 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 9988.04% in 2021, then soared by 151911.76% in 2024.
  • Quarter analysis of 5 years shows IceCure Medical's Cash from Financing Activities stood at $16.2 million in 2021, then decreased by 16.4% to $13.6 million in 2022, then tumbled by 99.5% to $68000.0 in 2023, then surged by 1519.12% to $1.1 million in 2024, then surged by 578.2% to $7.5 million in 2025.
  • Its Cash from Financing Activities was $7.5 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.6 million in Q1 2025.